Sanara MedTech, Inc. engages in the development, marketing, and distribution of biotechnology products to physicians, hospitals, and clinics. The company is headquartered in Fort Worth, Texas and currently employs 141 full-time employees. Its Sanara Surgical segment primarily markets and sells soft tissue repair and bone fusion products for use in the operating room or other sterile environments. Its Tissue Health Plus segment is focused on value-based wound care services. The company markets and distributes CellerateRX Surgical Activated Collagen, FORTIFY TRG Tissue Repair Graft and FORTIFY FLOWABLE Extracellular Matrix as well as a portfolio of advanced biologic products focusing on ACTIGEN Verified Inductive Bone Matrix, ALLOCYTE Plus Advanced Viable Bone Matrix, BiFORM Bioactive Moldable Matrix, TEXAGEN Amniotic Membrane Allograft, and BIASURGE Advanced Surgical Solution to the surgical market. BIAKOS Antimicrobial Wound Gel and others are the products sold in the wound care market.
How did SMTI's recent EPS compare to expectations?
The most recent EPS for Sanara Medtech Inc is $0.09, not beating expectations of $0.11.
How did Sanara Medtech Inc SMTI's revenue perform in the last quarter?
Sanara Medtech Inc revenue for the last quarter is $0.09
What is the revenue estimate for Sanara Medtech Inc?
According to 4 of Wall street analyst, the revenue estimate of Sanara Medtech Inc range from $30.87M to $27.34M
What's the earning quality score for Sanara Medtech Inc?
Sanara Medtech Inc has a earning quality score of A-/58.244965. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Sanara Medtech Inc report earnings?
Sanara Medtech Inc next earnings report is expected in 2026-06-22
What are Sanara Medtech Inc's expected earnings?
Sanara Medtech Inc expected earnings is $27.94M, according to wall-street analysts.
Did Sanara Medtech Inc beat earnings expectations?
Sanara Medtech Inc recent earnings of $27.54M does not beat expectations.
